Young Potenza’s Promise Attracts Astellas As Potential Buyer
This article was originally published in PharmAsia News
Astellas has secured an option to acquire the U.S. biotech Potenza as part of a new R&D alliance focusing on immuno-oncology candidates.
You may also be interested in...
New venture DigiTx will give Astellas a leg up in its quest to access novel digital health technologies, in a move unveiled as the Japanese firm reported continued strong growth for top product Xtandi.
In this week's podcast edition of Five Must-Know Things: the biggest drug launches expected in 2024; Roche’s Pharma CEO talks about growth momentum; 10 pivotal studies to look out for this year; the obesity market now and in future; and what does 2024 hold for transformative technology in biopharma.
In this week's podcast edition of Five Must-Know Things: Bayer’s pipeline refresh; J&J’s selective pharma M&A approach; silver lining for Gilead’s Trodelvy miss?; paying for obesity drugs; and the story behind Vertex and CRISPR’s gene therapy breakthrough.